Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983;25(3):287-92.
doi: 10.1007/BF01037935.

Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure

Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure

T Pedersen et al. Eur J Clin Pharmacol. 1983.

Abstract

The acute haemodynamic effects of the beta-adrenoreceptor agonist, prenalterol, were studied in six patients with chronic end-stage renal failure. Prenalterol 0.8 mg, 1.6 mg, and 3.2 mg was administered i.v. as a bolus, and after the last dose the selective adrenergic beta-1-receptor antagonist metoprolol was administered i.v. in doses of 5 and 10 mg. The haemodynamic effects of the drugs were investigated using impedance cardiography and radionuclide angiocardiography. The main haemodynamic effects were a dose-related chronotropic effect, demonstrated by an increase in heart rate (26%; less than 0.05), and an inotropic effect, shown by an increase in stroke volume index (20%; p less than 0.05) and left ventricular ejection time (12%; p less than 0.05); the cardiac index was increased by 47% (p less than 0.05). Transmural myocardial perfusion (DPTI/SPTI ratio) was decreased by 22% (p less than 0.05) after prenalterol. It is concluded that prenalterol has positive inotropic and chronotropic effects in patients with chronic renal failure, that the improvement in left ventricular performance is at the expense of a decreased transmural myocardial perfusion, and that metoprolol is a specific antidote.

PubMed Disclaimer

References

    1. Eur J Clin Pharmacol. 1980 Oct;18(3):219-23 - PubMed
    1. Lancet. 1980 Jan 19;1(8160):112-4 - PubMed
    1. Br J Clin Pharmacol. 1979 Apr;7(4):365-70 - PubMed
    1. Med Biol Eng. 1973 May;11(3):336-9 - PubMed
    1. Br Heart J. 1979 Aug;42(2):139-46 - PubMed

LinkOut - more resources